Holen Sie sich die Stockscreener-App
25.73
2.05%
-0.56
Handel nachbörslich:
25.73
Schlusskurs vom Vortag:
$26.29
Offen:
$25.84
24-Stunden-Volumen:
710.38K
Relative Volume:
0.89
Marktkapitalisierung:
$1.55B
Einnahmen:
$439.00K
Nettoeinkommen (Verlust:
$-105.64M
KGV:
-14.29
EPS:
-1.8
Netto-Cashflow:
$-60.70M
1W Leistung:
+13.49%
1M Leistung:
+7.07%
6M Leistung:
-11.05%
1J Leistung:
-47.82%
1-Tages-Spanne:
$25.26
$26.22
1-Wochen-Bereich:
$22.60
$26.73
52-Wochen-Spanne:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
25.73 | 1.58B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Can Janux Therapeutics Inc. stock surprise with earnings upsideTake Profit & Verified Swing Trading Watchlist - newser.com
Is Janux Therapeutics Inc. stock attractive for income investorsJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
Can trapped investors hope for a rebound in Janux Therapeutics Inc.Market Performance Report & Stock Portfolio Risk Control - newser.com
Is Janux Therapeutics Inc. stock poised for growthWeekly Loss Report & High Return Stock Watch Alerts - newser.com
Real time alert setup for Janux Therapeutics Inc. performanceProduct Launch & Fast Entry Momentum Alerts - newser.com
Janux Therapeutics (JANX) Is Up 10.5% After Positive Pipeline Updates and Analyst EPS Revisions – Has the Bull Case Changed? - Sahm
Why Janux Therapeutics (JANX) Is Up 10.5% After Pipeline Progress Fuels Optimism for Prostate Cancer Therapies - Yahoo Finance
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Trend analysis for Janux Therapeutics Inc. this weekPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance
What drives Janux Therapeutics Inc stock priceEarnings Per Share Trends & Rapid Portfolio Gain - earlytimes.in
Weiss Ratings Reaffirms Sell (D-) Rating for Janux Therapeutics (NASDAQ:JANX) - MarketBeat
Visual trend scoring systems applied to Janux Therapeutics Inc.Market Movement Recap & Accurate Entry and Exit Point Alerts - newser.com
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans - Sahm
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring the 245% Upside Potential in Biotech - DirectorsTalk Interviews
How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will a bounce in Janux Therapeutics Inc. offer an exitMarket Movement Recap & AI Enhanced Trading Signals - newser.com
How geopolitical tensions affect Janux Therapeutics Inc. stock2025 Momentum Check & Risk Controlled Stock Pick Alerts - newser.com
Janux Therapeutics Inc. recovery potential after sell offDollar Strength & Real-Time Volume Surge Alerts - newser.com
Leading vs lagging indicators on Janux Therapeutics Inc. performanceJuly 2025 Outlook & Community Supported Trade Ideas - newser.com
Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Janux Therapeutics(JANX.US) With Buy Rating - 富途牛牛
What earnings revisions data tells us about Janux Therapeutics Inc.Recession Risk & Daily Profit Maximizing Tips - newser.com
Using data tools to time your Janux Therapeutics Inc. exitWeekly Trend Summary & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-10-03 01:15:11 - newser.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $78.31 Average PT from Brokerages - Defense World
Will Q4 Earnings Be a Catalyst for Jash Engineering LimitedDay Trading Setups & Affordable Investment Tips - earlytimes.in
Published on: 2025-09-29 03:27:23 - newser.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Analysts - MarketBeat
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):